Healthcare / BiotechnologyTokyo
$58.00
-1.00 (-1.69%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 20%
FCF escenarios
weak_data · normalized FCF $-1.2B · quality 54.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
31/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$8.1B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-37.3%
↓Gross Margin
-22.5%
↓Debt/Equity
0.07
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+37.2%
FCF CAGR
—
FCF margin
-2782.4%
FCF / Net income
0.88x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $21.3M · net income $-676.3M · FCF $-593.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $21.3M | $21.3M | $27.2M | $39.9M | $8.3M |
| Net Income | $-676.3M | $-676.3M | $-1.33B | $-1.49B | $-2.02B |
| EBITDA | $-675.4M | $-675.4M | $-1.26B | $-1.39B | $-1.95B |
| EPS | -10.59 | -10.59 | -23.65 | -26.79 | -40.92 |
| Gross Margin | -22.5% | -22.5% | 81.0% | 70.5% | 29.5% |
| Operating Margin | -4194.3% | -4194.3% | -4948.7% | -3770.7% | -24691.3% |
| Net Margin | -3169.7% | -3169.7% | -4902.2% | -3734.6% | -24423.4% |
| Balance Sheet | |||||
| Debt/Equity | 0.07 | 0.07 | 0.05 | 0.10 | 0.09 |
| Current Ratio | 9.91 | 9.91 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-593.6M | $-593.6M | $-1.24B | $-1.40B | $-2.14B |
| Returns | |||||
| ROE | -37.3% | -37.3% | -95.9% | -56.3% | -51.0% |
| Valuation | |||||
| P/B | 2.04 | 2.04 | 2.15 | 1.64 | 1.42 |
| Growth & Yield | |||||
| Revenue Growth | -21.5% | -21.5% | -31.8% | 383.2% | — |
| EPS Growth | 55.2% | 55.2% | 11.7% | 34.5% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+28.9%
Start / end P/E
n/dx → n/dx
EPS bridge
-23.65 → -10.59
Residual
+28.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.